Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenshitong is a traditional Chinese medicine (TCM) formulation developed and manufactured by Liaoning Jindan Pharmaceutical. It is an approved therapeutic in China, primarily indicated for the treatment of urinary tract stones (urolithiasis), including kidney stones (nephrolithiasis), ureteral stones, and bladder stones. The formulation is a complex mixture of herbal ingredients, such as Desmodium (Jin Qian Cao), Vaccaria seed (Wang Bu Liu Xing), and Lygodium spore (Hai Jin Sha). Shenshitong exerts its therapeutic effects by promoting diuresis to increase urine flow, reducing inflammation in the urinary tract, and providing antispasmodic relief to the smooth muscles of the ureter. These actions facilitate the dissolution, fragmentation, and passage of calculi while alleviating associated symptoms like renal colic and dysuria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenshitong.